Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Encorafenib

FDA-approved product (capsule, oral), marketed as Braftovi.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Encorafenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal neoplasm
  • Cutaneous melanoma
  • Melanoma
  • Metastatic melanoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
B-raf serine-threonine kinase (braf) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Encorafenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Encorafenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

    NCT03973918 · start 2019-07-29

    Registered record
    Registry ID
    NCT03973918
    Conditions
    High Grade Glioma; BRAF V600E; BRAF V600K; Anaplastic Astrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Gliosarcoma; Glioblastoma
    Interventions
    Encorafenib; Binimetinib; Research Bloods; Tumor Tissue
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-07-29
    Completion
    2023-10-01
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Grade Glioma; BRAF V600E; BRAF V600K; Anaplastic Astrocytoma +3 more
    InterventionEncorafenib; Binimetinib; Research Bloods; Tumor Tissue
    PhasePhase 2
    Registry statusTerminated

  • Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

    NCT03898908 · start 2019-07-18

    Registered record
    Registry ID
    NCT03898908
    Conditions
    Metastatic Melanoma; Brain Metastases
    Interventions
    encorafenib; binimetinib; Whole brain radiation therapy; Radiosurgery/stereotactic radiosurgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-07-18
    Completion
    2023-07-31
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Melanoma; Brain Metastases
    Interventionencorafenib; binimetinib; Whole brain radiation therapy; Radiosurgery/stereotactic radiosurgery
    PhasePhase 2
    Registry statusCompleted

  • A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

    NCT03843775 · start 2019-02-14

    Registered record
    Registry ID
    NCT03843775
    Conditions
    Advanced BRAF Mutant Cancers
    Interventions
    Binimetinib; Encorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-02-14
    Completion
    2023-09-02
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced BRAF Mutant Cancers
    InterventionBinimetinib; Encorafenib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

    NCT03235245 · start 2018-10-30

    Registered record
    Registry ID
    NCT03235245
    Conditions
    Unresectable Stage III Melanoma; Stage IV Melanoma
    Interventions
    Nivolumab + Ipilimumab; Encorafenib + Binimetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-10-30
    Completion
    2027-01
    Enrolment
    271

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnresectable Stage III Melanoma; Stage IV Melanoma
    InterventionNivolumab + Ipilimumab; Encorafenib + Binimetinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

    NCT03543969 · start 2018-06-14

    Registered record
    Registry ID
    NCT03543969
    Conditions
    Melanoma (Skin); Skin Cancer; Skin Melanoma; Skin Carcinoma
    Interventions
    Encorafenib; Binimetinib; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2018-06-14
    Completion
    2026-12
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma (Skin); Skin Cancer; Skin Melanoma; Skin Carcinoma
    InterventionEncorafenib; Binimetinib; Nivolumab
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

    NCT02902042 · start 2018-04-24

    Registered record
    Registry ID
    NCT02902042
    Conditions
    Malignant Melanoma
    Interventions
    Encorafenib; Binimetinib; Pembrolizumab; Pembrolizumab alone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-04-24
    Completion
    2020-11-30
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Melanoma
    InterventionEncorafenib; Binimetinib; Pembrolizumab; Pembrolizumab alone
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

    NCT02631447 · start 2016-11-14

    Registered record
    Registry ID
    NCT02631447
    Conditions
    Metastatic Melanoma
    Interventions
    LGX818; MEK162; Nivolumab; Ipilimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-11-14
    Completion
    2024-05-31
    Enrolment
    251

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Melanoma
    InterventionLGX818; MEK162; Nivolumab; Ipilimumab
    PhasePhase 2
    Registry statusCompleted

  • A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

    NCT02857270 · start 2016-09-29

    Registered record
    Registry ID
    NCT02857270
    Conditions
    Advanced Cancer; Metastatic Melanoma; Metastatic Non-small Cell Lung Cancer; Colorectal Cancer
    Interventions
    LY3214996; Midazolam; Abemaciclib; Nab-paclitaxel; Gemcitabine; Encorafenib; Cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-09-29
    Completion
    2022-10-24
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer; Metastatic Melanoma; Metastatic Non-small Cell Lung Cancer; Colorectal Cancer
    InterventionLY3214996; Midazolam; Abemaciclib; Nab-paclitaxel +3 more
    PhasePhase 1
    Registry statusCompleted

  • BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

    NCT02834364 · start 2016-06

    Registered record
    Registry ID
    NCT02834364
    Conditions
    Relapsed or Refractory Multiple Myeloma; Patients With BRAFV600 E or BRAFV600K Mutation
    Interventions
    Encorafenib; Binimetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-06
    Completion
    2023-03-29
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Multiple Myeloma; Patients With BRAFV600 E or BRAFV600K Mutation
    InterventionEncorafenib; Binimetinib
    PhasePhase 2
    Registry statusCompleted

  • A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

    NCT02382549 · start 2016-04

    Registered record
    Registry ID
    NCT02382549
    Conditions
    Melanoma
    Interventions
    BRAF inhibitor; 6MHP; MEK inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2016-04
    Completion
    2022-02-28
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionBRAF inhibitor; 6MHP; MEK inhibitor
    PhaseEarly phase 1
    Registry statusTerminated

  • CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

    NCT02675946 · start 2016-02

    Registered record
    Registry ID
    NCT02675946
    Conditions
    Solid Tumors; GI Cancer
    Interventions
    CGX1321; Pembrolizumab; encorafenib; cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2016-02
    Completion
    2023-03
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors; GI Cancer
    InterventionCGX1321; Pembrolizumab; encorafenib; cetuximab
    PhasePhase 1
    Registry statusUnknown

  • Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

    NCT02109653 · start 2015-06

    Registered record
    Registry ID
    NCT02109653
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    LGX818
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2015-06
    Completion
    2017-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionLGX818
    PhasePhase 2
    Registry statusWithdrawn

  • Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

    NCT02263898 · start 2015-01

    Registered record
    Registry ID
    NCT02263898
    Conditions
    Recurrent Melanoma; Stage IV Melanoma
    Interventions
    Raf kinase inhibitor LGX818; binimetinib; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2015-01
    Completion
    2020-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Melanoma; Stage IV Melanoma
    InterventionRaf kinase inhibitor LGX818; binimetinib; laboratory biomarker analysis
    PhasePhase 2
    Registry statusWithdrawn

  • LGX818 for Patients With BRAFV600 Mutated Tumors

    NCT01981187 · start 2014-01-14

    Registered record
    Registry ID
    NCT01981187
    Conditions
    Solid Tumor; Hematologic Malignancies
    Interventions
    LGX818
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-01-14
    Completion
    2015-10-13
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor; Hematologic Malignancies
    InterventionLGX818
    PhasePhase 2
    Registry statusTerminated

  • LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma

    NCT01820364 · start 2013-11

    Registered record
    Registry ID
    NCT01820364
    Conditions
    Melanoma
    Interventions
    LGX818
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-11
    Completion
    2015-03
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionLGX818
    PhasePhase 2
    Registry statusTerminated